LEAP-005 Clinical Trial Baseline Demographics for Advanced Cancers

Baseline demographics and disease characteristics from the Phase II LEAP-005 clinical trial. The dataset details patient information for a study on lenvatinib plus pembrolizumab treatment for advanced gastric, biliary tract, or pancreatic cancer. It was authored by Mariano Ponz-Sarvisé and published under a CC BY license.

Use Cases

• Analyze baseline demographics across gastric, biliary tract, and pancreatic cancer patient subgroups.
• Correlate disease characteristics with treatment outcomes reported in the LEAP-005 study.
• Benchmark patient cohort profiles against other oncology clinical trial datasets.

Strengths

• Data originates from a structured Phase II clinical trial (LEAP-005).
• Covers three distinct advanced cancer types: gastric, biliary tract, and pancreatic.
• Published under a permissive CC BY license for reuse.

Limitations

• Very small scale at 9.5 KB, indicating limited record count.
• Contains only baseline data, lacking subsequent treatment response or survival outcomes.
• Column names and row count are unspecified, limiting analytical planning.

Provenance

Source

figshare, authored by Mariano Ponz-Sarvisé.

Collection Method

Collected as part of the Phase II LEAP-005 clinical study.

Time Range

null

Freshness

Last updated March 2026.

Geography

null